Board appointments at Algeta
This article was originally published in Scrip
Algeta (Norway), an oncology-focused company developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform, has elected Dr Judith Hemberger and Dr Kapil Dhingra non-executive directors. Dr Hemberger has more than 30 years' pharmaceutical and biotech industry experience, having most recently served as a venture partner at Nomura Phase4 Ventures and interim CEO of Zosano Pharma. Before that Dr Hemberger was co-founder, executive vice-president and chief operating officer of Pharmion. Dr Dhingra was formerly vice-president, head of the oncology disease biology leadership team, and head of oncology clinical development at Roche. Before that, he was clinical and senior clinical research physician at Lilly.